GSK has acquired CMG1A46, a dual CD19 and CD20-targeted T cell-engager from Chimagen for $300M upfront.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
GSK has acquired CMG1A46, a dual CD19 and CD20-targeted T cell-engager from Chimagen for $300M upfront.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
We are preparing, please wait
This content is only available for premium members. Please become a paid member to access.
Download AppCurrently, memberships can only be purchased through the app.